Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1999 Nov;81(6):1031–1036. doi: 10.1038/sj.bjc.6690803

Ifosfamide, cisplatin and etoposide combination in locally advanced inoperable non-small-cell lung cancer: a phase II study

A F Scinto 1, V Ferraresi 1, M Milella 1, E Tucci 4, C Santomaggio 5, R Pasquali-Lasagni 2, M R Del Vecchio 3, N Campioni 2, M Nardi 1, F Cognetti 1
PMCID: PMC2362939  PMID: 10576661

Abstract

From March 1993 to February 1997, 43 eligible patients with inoperable stage IIIA (ten patients) and stage IIIB (33 patients), histologically confirmed NSCLC received 3 courses of the ICE combination (ifosfamide 1.5 g m−2 and mesna 750 mg m−2 two times a day, cisplatin 25 mg m−2 and etoposide 100 mg m−2, all administered intravenously (i.v.) on days 1–3 every 3 weeks) with G-CSF support. After three cycles, patients were submitted to radical surgery or received two additional courses of the ICE regimen and/or curative radiotherapy. Grade 3–4 neutropenia occurred in 21% of 114 evaluable courses, but was of short duration, leading to neutropenic fever in 5% of the courses. Severe thrombocytopenia and anaemia were observed in 13% and 3% of the courses respectively. Non-haematological toxicity was generally mild with only two episodes of reversible renal impairment. The overall response rate after three chemotherapy courses was 69% (28 partial responses, one complete response). Ten patients (8/10 patients in stage IIIA, 2/33 patients in stage IIIB) underwent radical surgery. Median TTP for patients not undergoing surgery (n = 33) was 8 months (range 3–34+); median DFS for patients rendered NED by surgery (n = 10) was 26 months (range 1–54+). Median OS for the entire group was 12.5 months (range 2–57+). The ICE regimen is active in locally advanced NSCLC with acceptable toxicity and warrants further exploration as induction chemotherapy in larger series. © 1999 Cancer Research Campaign

Keywords: non-small-cell lung cancer, locally advanced, inoperable, chemotherapy, ICE, G-CSF

Full Text

The Full Text of this article is available as a PDF (76.7 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ardizzoni A., Fusco V., Gulisano M., Pronzato P., Baracco F., Capaccio A., Pastorino G., Nosenzo M., Felletti R., Fabiano F. Etoposide, ifosfamide, and cisplatin in the treatment of advanced non-small cell lung cancer. Cancer Treat Rep. 1987 Dec;71(12):1311–1312. [PubMed] [Google Scholar]
  2. Bonomi P, Faber LP. Postoperative and Preoperative Chemotherapy for Non-Small Cell Lung Cancer. Cancer Control. 1997 Jul;4(4):297–306. doi: 10.1177/107327489700400401. [DOI] [PubMed] [Google Scholar]
  3. Eberhardt W., Niederle N. Ifosfamide in non-small cell lung cancer: a review. Semin Oncol. 1992 Feb;19(1 Suppl 1):40–48. [PubMed] [Google Scholar]
  4. Elias A. D., Skarin A. T., Leong T., Mentzer S., Strauss G., Lynch T., Shulman L., Jacobs C., Abner A., Baldini E. H. Neoadjuvant therapy for surgically staged IIIA N2 non-small cell lung cancer (NSCLC). Lung Cancer. 1997 May;17(1):147–161. doi: 10.1016/s0169-5002(97)00658-2. [DOI] [PubMed] [Google Scholar]
  5. Fischer J. R., Manegold C., Bülzebruck H., Vogt-Moykopf I., Drings P. Induction chemotherapy with and without recombinant human granulocyte colony-stimulating factor support in locally advanced stage IIIA/B non-small cell lung cancer. Semin Oncol. 1994 Jun;21(3 Suppl 4):20–27. [PubMed] [Google Scholar]
  6. Martini N., Kris M. G., Flehinger B. J., Gralla R. J., Bains M. S., Burt M. E., Heelan R., McCormack P. M., Pisters K. M., Rigas J. R. Preoperative chemotherapy for stage IIIa (N2) lung cancer: the Sloan-Kettering experience with 136 patients. Ann Thorac Surg. 1993 Jun;55(6):1365–1374. doi: 10.1016/0003-4975(93)91072-u. [DOI] [PubMed] [Google Scholar]
  7. Miller A. B., Hoogstraten B., Staquet M., Winkler A. Reporting results of cancer treatment. Cancer. 1981 Jan 1;47(1):207–214. doi: 10.1002/1097-0142(19810101)47:1<207::aid-cncr2820470134>3.0.co;2-6. [DOI] [PubMed] [Google Scholar]
  8. Paccagnella A., Favaretto A., Brandes A., Ghiotto C., Fornasiero A., Volpi A., Pappagallo G., Festi G., Cipriani A., Vinante O. Cisplatin, etoposide, and ifosfamide in non-small cell lung carcinoma. A phase II randomized study with cisplatin and etoposide as the control arm. Cancer. 1990 Jun 15;65(12):2631–2634. doi: 10.1002/1097-0142(19900615)65:12<2631::aid-cncr2820651205>3.0.co;2-y. [DOI] [PubMed] [Google Scholar]
  9. Perez C. A., Pajak T. F., Rubin P., Simpson J. R., Mohiuddin M., Brady L. W., Perez-Tamayo R., Rotman M. Long-term observations of the patterns of failure in patients with unresectable non-oat cell carcinoma of the lung treated with definitive radiotherapy. Report by the Radiation Therapy Oncology Group. Cancer. 1987 Jun 1;59(11):1874–1881. doi: 10.1002/1097-0142(19870601)59:11<1874::aid-cncr2820591106>3.0.co;2-z. [DOI] [PubMed] [Google Scholar]
  10. Perez E. A., Sowray P. C., Gardner S. L., Gandara D. R. Phase I study of high-dose cisplatin, ifosfamide, and etoposide. Cancer Chemother Pharmacol. 1994;34(4):331–334. doi: 10.1007/BF00686041. [DOI] [PubMed] [Google Scholar]
  11. Pujol J. L., Rossi J. F., Le Chevalier T., Daurès J. P., Rouanet P., Douillard J. Y., Dubois J. B., Arriagada R., Mary H., Godard P. Pilot study of neoadjuvant ifosfamide, cisplatin, and etoposide in locally advanced non-small cell lung cancer. Eur J Cancer. 1990;26(7):798–801. doi: 10.1016/0277-5379(90)90155-m. [DOI] [PubMed] [Google Scholar]
  12. Rosell R., Gómez-Codina J., Camps C., Maestre J., Padille J., Cantó A., Mate J. L., Li S., Roig J., Olazábal A. A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer. N Engl J Med. 1994 Jan 20;330(3):153–158. doi: 10.1056/NEJM199401203300301. [DOI] [PubMed] [Google Scholar]
  13. Rosell R., López-Cabrerizo M. P., Astudillo J. Preoperative chemotherapy for stage IIIA non-small cell lung cancer. Curr Opin Oncol. 1997 Mar;9(2):149–155. doi: 10.1097/00001622-199703000-00008. [DOI] [PubMed] [Google Scholar]
  14. Roth J. A., Fossella F., Komaki R., Ryan M. B., Putnam J. B., Jr, Lee J. S., Dhingra H., De Caro L., Chasen M., McGavran M. A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer. J Natl Cancer Inst. 1994 May 4;86(9):673–680. doi: 10.1093/jnci/86.9.673. [DOI] [PubMed] [Google Scholar]
  15. Shepherd F. A., Evans W. K., Goss P. E., Latreille J., Logan D., Maroun J., Stewart D., Warner E., Paul K. Ifosfamide, cisplatin, and etoposide (ICE) in the treatment of advanced non-small cell lung cancer. Semin Oncol. 1992 Feb;19(1 Suppl 1):54–58. [PubMed] [Google Scholar]
  16. Shirinian M., Lee J. S., Dhingra H. H., Greenberg J., Hong W. K. Phase II study of cisplatin, ifosfamide, and etoposide combination for advanced non-small cell lung cancer: final report. Semin Oncol. 1992 Dec;19(6 Suppl 12):58–63. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES